Cargando…
Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study
High-density lipoproteins (HDLs) are promising targets for predicting and treating atherosclerotic cardiovascular disease (ASCVD), as they mediate removal of excess cholesterol from lipid-laden macrophages that accumulate in the vasculature. This functional property of HDLs, termed cholesterol efflu...
Autores principales: | Gangwar, Anamika, Deodhar, Sneha S., Saldanha, Suzanne, Melander, Olle, Abbasi, Fahim, Pearce, Ryan W., Collier, Timothy S., McPhaul, Michael J., Furtado, Jeremy D., Sacks, Frank M., Merrill, Nathaniel J., McDermott, Jason E., Melchior, John T., Rohatgi, Anand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648649/ https://www.ncbi.nlm.nih.gov/pubmed/37958510 http://dx.doi.org/10.3390/ijms242115526 |
Ejemplares similares
-
Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study)
por: Akinmolayemi, Oludamilola, et al.
Publicado: (2021) -
Identification of the Underlying Androgen Receptor Defect in the Dallas Reifenstein Family
por: Ahmad, Zahid, et al.
Publicado: (2017) -
Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population: Insights From MESA
por: Hunter, Wynn G., et al.
Publicado: (2023) -
OR02-2 The Relationship of Lipoprotein Fractions as Assessed by Ion Mobility and Insulin Resistance as Measured by the Insulin Suppression Test
por: Abbasi, Fahim, et al.
Publicado: (2022) -
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)